Zacks Research Comments on ResMed Inc.'s Q1 2025 Earnings (NYSE:RMD)

ResMed Inc. (NYSE:RMD - Free Report) - Zacks Research increased their Q1 2025 earnings per share estimates for shares of ResMed in a note issued to investors on Monday, April 8th. Zacks Research analyst R. Department now anticipates that the medical equipment provider will earn $1.94 per share for the quarter, up from their prior estimate of $1.93. The consensus estimate for ResMed's current full-year earnings is $7.45 per share. Zacks Research also issued estimates for ResMed's FY2025 earnings at $8.04 EPS and FY2026 earnings at $8.65 EPS.

ResMed (NYSE:RMD - Get Free Report) last issued its quarterly earnings data on Wednesday, January 24th. The medical equipment provider reported $1.88 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.81 by $0.07. ResMed had a return on equity of 23.86% and a net margin of 19.77%. The business had revenue of $1.16 billion for the quarter, compared to the consensus estimate of $1.15 billion. During the same period in the prior year, the business earned $1.66 earnings per share. The business's revenue was up 12.5% on a year-over-year basis.

Several other brokerages also recently issued reports on RMD. Oppenheimer upped their price objective on shares of ResMed from $185.00 to $205.00 and gave the company an "outperform" rating in a research note on Tuesday, January 30th. Royal Bank of Canada lifted their price objective on ResMed from $181.00 to $182.00 and gave the company a "sector perform" rating in a research report on Thursday, January 25th. UBS Group increased their target price on ResMed from $175.00 to $180.00 and gave the stock a "neutral" rating in a research report on Thursday, January 25th. JPMorgan Chase & Co. raised their price target on ResMed from $160.00 to $195.00 and gave the stock an "overweight" rating in a research note on Tuesday, January 9th. Finally, Mizuho reaffirmed a "buy" rating and set a $215.00 price objective on shares of ResMed in a research note on Wednesday, March 27th. Four equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $199.20.

ResMed Trading Down 2.2 %

Shares of ResMed stock traded down $4.29 during mid-day trading on Thursday, hitting $189.51. 696,180 shares of the stock were exchanged, compared to its average volume of 987,638. The stock has a market capitalization of $27.88 billion, a price-to-earnings ratio of 31.32, a price-to-earnings-growth ratio of 2.32 and a beta of 0.67. ResMed has a twelve month low of $132.24 and a twelve month high of $243.52. The company has a current ratio of 3.11, a quick ratio of 1.89 and a debt-to-equity ratio of 0.27. The company has a 50-day simple moving average of $187.01 and a 200 day simple moving average of $168.98.

ResMed Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Thursday, March 14th. Investors of record on Thursday, February 8th were issued a $0.48 dividend. The ex-dividend date of this dividend was Wednesday, February 7th. This represents a $1.92 annualized dividend and a yield of 1.01%. ResMed's payout ratio is 31.74%.

Insider Buying and Selling at ResMed

In related news, Director Peter C. Farrell sold 10,935 shares of the company's stock in a transaction on Thursday, February 22nd. The shares were sold at an average price of $182.66, for a total transaction of $1,997,387.10. Following the completion of the sale, the director now directly owns 157,404 shares of the company's stock, valued at approximately $28,751,414.64. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other ResMed news, General Counsel Michael J. Rider sold 200 shares of the stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $173.25, for a total value of $34,650.00. Following the completion of the sale, the general counsel now owns 6,688 shares of the company's stock, valued at $1,158,696. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Peter C. Farrell sold 10,935 shares of ResMed stock in a transaction that occurred on Thursday, February 22nd. The shares were sold at an average price of $182.66, for a total transaction of $1,997,387.10. Following the sale, the director now owns 157,404 shares in the company, valued at approximately $28,751,414.64. The disclosure for this sale can be found here. Insiders have sold a total of 11,216 shares of company stock valued at $2,046,617 over the last ninety days. Corporate insiders own 1.21% of the company's stock.

Institutional Investors Weigh In On ResMed

A number of large investors have recently added to or reduced their stakes in RMD. Synergy Asset Management LLC boosted its position in ResMed by 29.2% in the 4th quarter. Synergy Asset Management LLC now owns 69,383 shares of the medical equipment provider's stock valued at $11,935,000 after buying an additional 15,663 shares during the last quarter. Inspire Advisors LLC boosted its holdings in ResMed by 20.2% in the third quarter. Inspire Advisors LLC now owns 1,553 shares of the medical equipment provider's stock valued at $230,000 after purchasing an additional 261 shares during the last quarter. Nordea Investment Management AB grew its stake in ResMed by 3.4% during the 4th quarter. Nordea Investment Management AB now owns 9,753 shares of the medical equipment provider's stock valued at $1,682,000 after purchasing an additional 324 shares in the last quarter. Miracle Mile Advisors LLC purchased a new stake in ResMed during the 4th quarter worth approximately $275,000. Finally, Mackenzie Financial Corp raised its position in shares of ResMed by 12.6% in the 3rd quarter. Mackenzie Financial Corp now owns 151,505 shares of the medical equipment provider's stock valued at $21,906,000 after purchasing an additional 16,966 shares in the last quarter. 54.98% of the stock is owned by institutional investors and hedge funds.

About ResMed

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. It operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes.